

出國報告（出國類別：其他）

參加 2017 年北美生技展  
(2017 BIO International  
Convention) 出國報告

服務機關：衛生福利部

姓名職稱：何啟功 政務次長

何承穎 研發替代役助理研究員

派赴國家：美國

出國期間：106 年 6 月 18 日至 6 月 25 日

報告日期：106 年 9 月

公務出國報告提要

參加 2017 年北美生技展出國報告

頁數：29 頁 含附件：是 否

出國計畫主辦機關 / 聯絡人 / 電話

衛生福利部科技發展組/李顯揚研究員/02-85907567

出國人員姓名 / 服務機關 / 單位 / 職稱 / 電話

何啟功/衛生福利部/部長室/政務次長/02-85907710

何承穎/衛生福利部 /科技發展組/研發替代役助理研究員/02-85907564

出國類別：1 考察 2 進修 3 研究 4 實習 5 其他

出國地區：美國

報告日期：2017 年 9 月

## 摘要

BIO International Convention(北美生技展) 本次於 106 年 6 月 19 日 6 月 22 日假美國加州聖地牙哥的 San Diego Convention Center 舉辦，共計來自全世界 55 個國家代表團，16,000 位生技產業人士出席，超過 1,800 家公司參展，近千家公司參與媒合洽談，是全球生技界每年最大的產業活動平台。

本年度「台灣館」展區由財團法人中華民國對外貿易發展協會主辦，並依循過往的模式，由吳政忠政務委員組成台灣代表團參加本次展覽，計有 27 個相關單位參加，代表團共計 139 位成員，並促成了 463 場次的商機會議，大幅提升台灣在生技產業發展的機會。

本部於今年度的參展主題為「台灣卓越臨床中心-優質臨床試驗環境」，經由在這國際舞台推廣台灣優質的臨床試驗環境，以吸引國際廠商至我國進行臨床試驗的機會，藉此強化「提升台灣醫療研究的量能」、「幫助國人優先獲得新藥之機會」及「強化我國在國際新藥發展路程的實力」等優勢。

# 目次

摘要.....	3
壹、簡介及目的.....	5
貳、過程.....	7
參、心得及建議.....	18
肆、附件.....	20

## 壹、簡介及目的

美國生技展 (USA BIO) 在美國三大生技產業聚落之一的聖地牙哥盛大舉行。總計來自全世界 55 個國家代表團，超過 1,800 家公司參展，近千家公司參與媒合洽談。今年首次報名參加人數達 6,000 人，較去年成長 37%，估計將有 16,000 位生技產業人士出席，是全球生技界每年最大的產業活動平台，可促進搭起產、官、學界橫向合作的橋梁，故我國多年來皆組團參加這一年一度的盛事。

每年大會的議題、活動事件與論壇發表，往往扮演了國際生技產業各領域發展動向與趨勢的風向球，今年大會在 4 天之內，同時舉辦近 15 個不同主題討論共約 160 場論壇。包括「腦科學」、「數位醫療」、「全球新興市場商機」、「轉譯醫學」、「腫瘤醫療」、「個體醫療與診斷」、「孤兒藥開發」、「感染疾病與疫苗」、「現代農業革命」、「次世代新醫療」、「大數據與醫療革命」、「新能源」等。其中因應近兩年大數據引發醫療變革，以及氣候變遷下農業必須新科技解決等當下國際共同難題，今年特別設立大數據與農業論壇，據大會統計每天吸引約 7,000 人穿梭在各個論壇。

今年參展廠商包括台灣微脂體、太景生技、藥華醫藥、善笙生技、台灣浩鼎、逸達生技、杏國生技、健永生技、順天醫藥生技、永昕生

技、金樺生物醫學、展旺生技、台康生技以及台灣動藥、亞果、豬博士動物科技；政府與法人單位則有本部、中研院、科技部生科司、新竹科學工業園區管理局、南部科學工業園區管理局、農委會、生技中心、工研院生醫所、農業科技研究院、藥技中心、國家衛生研究院、國家實驗研究院、外貿協會、台灣生物產業發展協會、台灣研發型生技新藥發展協會等。每個研究單位及廠商皆努力爭取與國際廠商技轉或合作開發的機會，本部及其他政府單位亦積極招募有興趣來台投資的國家或機構及推廣台灣極佳的研究環境，以提升台灣在生技產業發展的軟、硬實力為共同目標。

## 貳、過程

### 一、行程表

6/17(週六)	(出發至美國 聖地牙哥)
於同日晚間抵達洛杉磯國際機場，並搭乘主辦單位安排之接駁車至聖地牙哥之下榻飯店。	
6/18(週日)	(上午-會場佈置；下午-參加臺灣生技商機論壇)
<ol style="list-style-type: none"><li>1. 上午 9:00 至 San Diego Convention Center 報到並索取參展吊牌及相關文件，再至台灣館確認會場佈置情形。</li><li>2. 下午 1 點整至 5 點 30 分至 Bayfront 飯店參加臺灣生技商機論壇 (Taiwan Biotech Forum)。</li></ol>	
6/19(週一)	(會場佈置及攤位諮詢服務；下午-與美國貿易代表署代表晤談)
<ol style="list-style-type: none"><li>1. 上午至下午進行攤位諮詢服務。</li><li>2. 下午 2 點於 San Diego Convention Center Room 23C 與美國貿易代表署代表會面晤談。</li></ol>	
6/20(週二)	(上下午-會場攤位諮詢服務；晚上-台灣團長致謝晚宴)
<ol style="list-style-type: none"><li>1. 上午至下午進行攤位諮詢服務。</li><li>2. 下午 4 點於台灣館參加開幕儀式。</li></ol>	

<p>3. 晚上 6 點至 San Diego the New Children's Museum 參加台灣團團長致謝晚宴。</p>	
<p><b>6/21(週三)</b></p>	<p>(上下午-會場攤位諮詢服務；晚上-台美日韓泰交流晚會)</p>
<p>1. 上午至下午進行攤位諮詢服務。</p> <p>2. 晚上 5 點半於 San Diego Wine and Culinary Center 參加台美日韓泰交流晚會。</p>	
<p><b>6/22(週四)</b></p>	<p>(上下午-會場攤位諮詢服務；晚上-撤展)</p>
<p>1. 上午至下午進行攤位諮詢服務。</p> <p>2. 下午 5 點半撤展。</p>	
<p><b>6/23(週五)</b></p>	<p>(上午-Illumina 參觀；晚上-返台)</p>
<p>1. 8 點半集合前往 Illumina 進行參訪。</p> <p>3. 下午 5 點半撤展。</p>	



## 二、 內容

### (一) 2017 臺灣生技論壇



Time	Topic	Speakers
12:30   13:00	Registration	
13:00   13:10	Welcome Remarks	Dr. Lawrence Gan, President, Development Center for Biotechnology, Taiwan (財團法人生技中心執行長 莊明哲)
13:10   13:30	Opening Remarks	Dr. Tsung-Tsong, Wu Minister without Portfolio, The Executive Yuan, Taiwan (行政院科技政策 吳政忠) Jaime Ming-Shy Chen, Deputy Director General, Taipei Economic and Cultural Office in Los Angeles (駐洛杉磯台灣經濟文化辦事處副處長 陳銘鈞)
13:30   14:00	Keynote Presentation 1 New Frontiers in the Search for Biomarkers: Early Identification and Intervention for Neuropsychiatric Disorders	Prof. Ming Tsuang, UCSD Endowed Chair in Behavioral Genomics/Academician, Academia Sinica (UCSD行為基因體研究所所長, 中研院院士 莊明哲 教授)
14:00   14:30	Keynote Presentation 2 From precision medicine to precision health care	Prof. Yun Yen, President, Taipei Medical University (台北醫學大學校長 嚴震)
14:30   14:50	Break	
14:50   15:20	Keynote Presentation 3 A Company Perspective on Pre-Innovation Policies	Penny Wan Vice President, Japan Asia Pacific (JAPAC) Amgen, Inc.
15:20   15:50	Keynote Presentation 4 All about the Business Development strategy	Johan Verbeek, Senior Director Licensing, Immunology & External Partnering Johnson & Johnson Innovation, Janssen Business Development • EisGenix, Inc. (信康生技) • Ferring Pharmaceuticals Co., Ltd. (海濱生技) • Lumosa Therapeutics Co., Ltd. (燭天醫藥生技) • Tactile Biotechnology Co., Ltd. (太康生技) • Taiwan Liposome Company Ltd. (台灣脂體藥) • Taiwan Pharmaceuticals Co., Ltd. (康復生技) • TPG Biologicals, Inc. (泰博生物醫藥)
15:50   17:00	Company Presentation	
17:00 	Speed Networking	Sponsored by pwc

本次會議於6月18日假聖地牙哥 Bayfront 飯店舉辦，為北美生技展開展的前一天，會上邀請吳政忠政務委員為大會開場致詞，讓代表團成員先初步了解國內外發展的現況，藉此確立本次台灣代表團出訪的目標。論壇中來自世界各地的重量級專家學者，與150位以上的生技專業人才，共同探討多項當紅主題包括精準醫療、生技醫藥發展、台灣生技創新和藥物的發展機會、全球夥伴和合作策略。更邀請聖地牙哥加大 (UCSD) 行為基因體研究所所長、中央研究院院士莊明哲

教授，由基因體定序的觀點來談精神分裂症的研究，以及試圖找出關鍵生物指標的重要性。




另，台北醫學大學閻雲校長亦受邀擔任本次論壇之演講貴賓，從學研角度探討台灣精準醫療現況，從前端精準預防、精準治療到後端精準醫療照護，配合大數據，未來將可從行為模式、飲食習慣預測疾

病的發生，訂定個人基因序列表，以有效協助醫師能更精準診斷病因。

## (二) 攤位展示






我國攤位本次以綠色系及蘭花圖騰為主，政府及法人單位各以一面獨立之背板做展示牆，形成開放式設計攤位；法人單位之展示牆另有裝設 iPad 及電視，以循環撥放各單位之簡介及研發亮點，政府及法人單位共計有 11 家。參展廠商並以三角形背板隔出展示空間，計有 15 個廠商攤位展出，每 2 個攤位配有 1 個供洽商使用的會議室，雖受限場地大小而略顯擁擠，但整體設計空間運用得宜且溫馨舒適。

而亞洲地區列舉日本、香港及韓國三星攤位亦可作為我未來參展之參考，日本館採較為嚴謹方正之風格，使用大片外牆包覆內部洽談區，有利於展示眾多成果但偏於封閉。香港館將展示看板自攤位中心以放射狀排列，方便觀展人員進出，並於展示海報前設置接待座位就近討論相關事宜。韓國三星館以藍與白代表色設計展館，於該展館設有服務台，以燈箱及電視展示研發成果，不僅給人簡約明亮的視覺概念，更透過觸控式螢幕進行細部介紹及互動，有利提升商機媒合。未來我國參展可因應不同需求及性質，調整攤位之設計及功能，以期能提升我國生醫產業於國際之行銷及推廣，帶動國內相關產業發展。

另，本部推廣「台灣卓越臨床中心-優質臨床試驗環境」為展覽主題，成功吸引各方人士在雙方攤位前駐足，並由本部帶領諮詢者了解我國優質的臨床試驗及生技研究環境，以增加各界藥廠至我國進行臨床試驗的機會。

### (三) 台灣館開幕會





台灣代表團由吳政忠政務委員進行台灣館開場致詞，本部何啟功次長、科技部蘇芳慶次長、中研院廖俊智院長、農委會、經濟部工業局及技術處、竹科管理局等部會官員，及生技醫藥相關法人、協會及參展廠商陪同下，共同揭開以國家形象呈現的台灣生技展館。今年開幕活動特別提供準備台灣金車噶瑪蘭威士忌做為台灣特色禮品，並舉辦現場抽獎，此開幕活動吸引廣大人潮，走道擠滿駐足來賓，據統計為近年來台灣生技館來賓最多的一次。吳政忠政委致詞時亦表示，從

研發環境面，台灣在臨床醫學與華人特有疾病研究具有國際優勢，並且建置了屬於台灣的人體生物資料庫(Taiwan Biobank)，加上臺灣醫療技術與環境已享譽國際，台灣擁有充分條件可以成為亞太生技醫藥產業的先期市場和試驗基地。此外，台灣中研院與台大、長庚等機構已參與美國癌症登月計畫(Cancer Moonshot) 初期階段，進入國際醫藥研發價值鏈，因此台灣具有極佳優勢條件成為各國發展生技醫藥的亞洲首選夥伴。此開幕活動成功凸顯出我國具有深厚的研發量能、卓越的生技人才及優良的生技環境，以吸引國際廠商來台投資及合作的機會。

#### (四) 台灣團長致謝晚宴







台灣致謝晚宴設於 San Diego the New Children's Museum 舉辦，  
並由團長吳政忠政委率領我國所有參展人員共同與會，除感謝我國參  
展人員對此次展覽之用心規劃與執行，並藉此活動聚本次出訪生技團  
的成員的向心力，也期望能進一步交織出產、官、學合作的無限可能。

## 參、心得及建議

- 一、經由參加北美生技展的機會除可提升同仁的國際觀，進一步了解國際間在生技產業的作為及脈動，亦可使同仁認識其他生技參訪團的成員，有助於未來在生技發展規劃中增加跨部會/單位的整合機會，並可藉由傳達本部的宗旨及任務，加強各國政府單位對我國的信任及認識。
- 二、我國相較其他國家在生技產業發展上深具潛力，另因國土狹小反而具產業高度整合性之機會，然而政府單位在此其中更扮演極重要的角色，而「生技醫藥產業」亦為政府重要發展策略，若經由參考他國的作為再結合我國的優勢，必定能進一步提升我國生技產業的發展環境。
- 三、本次展覽中，本部以推廣「台灣卓越臨床中心-優質臨床試驗環境」為展覽主題，吸引許多參觀人員的詢問及討論，惟可惜礙於攤位空間有限，展出資訊亦受限制。日後若能爭取更大的展示空間，應整合本部補助多年之傑出研究計畫與「財團法人國家衛生研究院」、「食品藥物管理署」、「疾病管制署」、「國民健康署」及「衛生福利部國家中醫藥研究所」等單位，由本部科技發展組代替未能參展之單位展出其豐碩的研究成果，藉以展現我國傑出的

研究量能及友善的研究環境。

四、因應國際資訊技術之進步，我國於本次參觀展會時，以掃描會員證上QR code之方式以收集參訪人員資料，可藉其收集資訊並建立相關資料庫，亦便於後續以mail發送相關訊息等，極具便利性且富科技元素。另，各國參展單位之宣導品亦各有其巧思，其中以VR眼鏡搭配手機下載宣導影片之方式，最為吸引參訪目光。

我國未來於參展時，亦可考量各式新興或符合我國特色之宣傳品，或於相關宣傳品或宣導單張上印製諮詢網址及專線電話，以及製作展會諮詢專屬名片，讓所有有興趣之參觀者即使未能在現場充份了解，亦能找到諮詢的窗口以及所需資訊。

五、本次台灣團代表成員皆委託同一旅行社代為預訂飯店，故多數成員（尤其是部會代表）均能在早餐時溝通交流各部會及相關單位對藥物臨床試驗及法規管理的經驗。此一安排有助於在會場時互相幫忙，在與國外相關領域的人士交流時，能更有效率的將對我們有興趣的廠商與業務單位進行媒合。彰顯政府對生技產業的完善分工與規劃，並有效提升我國生技產業之能見度與國際觀。

# 肆、附件

**Bio-Clusters**

- Over 100 research-focused companies
- 5,000+ graduates/year in life sciences
- 132 PIC/s GMP facilities
- 1.5 hrs travel time from north to south

**2017 BIO International Convention, Jun 19-22, 2017**  
Taiwan Pavilion - Booth: 1437, 1537

**Taiwan**

*Program*

**Taiwan Biotech Forum**  
Precision Medicine X Taiwan Opportunities  
Time & Date: 12:30-18:00, June 18<sup>th</sup> (Sunday) 2017  
Venue: C. Hilton Dayfront San Diego

**Taiwan Pavilion Opening Ceremony**  
Join us for award winning whiskey and signature food of Taiwan  
Time & Date: 16:00-17:00, June 20<sup>th</sup> (Tuesday) 2017  
Venue: Taiwan Pavilion (Booth no. 1437 & 1537)

**Bio Global Innovation Hub - Taiwan**  
Time & Date: 13:45-14:00, June 21<sup>st</sup> (Wednesday) 2017  
Venue: Spotlight Theatre, Sails Pavilion

**Map Data:**

- Hsinchu Biomedical Science Park** & **Hsinchu Science and Industrial Park**: 121 companies
  - New Drugs & Biologics
  - Medical Devices
  - ICT + Medical Imaging
- National Biotechnology Research Park**, **Taipei Nangang Biotech Plaza**, **Taipei Neihsu Technology Park**, **New Taipei Industrial Park**: 468 companies
  - New Drugs
  - Medical Devices
  - Diagnostics + Medical Electronics
- Central Taiwan Science Park**: 295 companies
  - Rehabilitation + Precision Instruments
  - Applied Biotechnology
  - Pharmaceuticals
- Southern Taiwan Science Park**: 205 companies
  - Pharmaceuticals
  - Medical Devices
- Taiwan Orchid Plantation** & **Pingtung Agricultural Biotech Park**

**Taiwan: Your Best Partner in Asia**  
from innovation to manufacturing

Taiwan Exhibitors Information  
**One stop service office**  
Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO)

**R&D Subsidies**

- Fast track approval (30 days) for grant applications
- Subsidies for R&D and clinical research incentive programs up to 49% of total budget

**Tax Benefits**

- Act for Development of Biotech and New Pharmaceutical Industry
  - Tax Reduction for R&D (up to 35% of R&D spending)
  - Tax Reduction for Personnel Training (up to 35% of personnel training spending)
  - Tax Credit for Shareholder's Investment (up to 30% of original cost of shares)
  - Statute for Industrial Innovation
- Tax Deferral for Technology Shares
- Tax Deferral for Stock Options

**IP Protection**

- Intellectual Property Office set up since 1999 (patent, trademark, copyright, IC layout, and trade secret)

**Fund**

- National Development Fund

**IPO Recommendation**

- Bio-related IPO companies with 17% increase of revenue

**Incentives**

New Drug / Product Development    Preclinical Study    Clinical Study    Production and Marketing

**Infrastructures & Resources**

**Academic and Research Institutes**

- Leads
- Drug Screening
- Platform

5,000+ graduates/year

99% citizens covered by "National Health Insurance" since 1995

77,200 samples in Taiwan Biobank

**Research Institutes**

- Lead Optimization
- Pharmacology
- Toxicology
- Preclinical Service Platform

**Taiwan FDA (set up since 2010)**

**Clinical Trial Centers of Excellence**

- Taiwan Clinical Trial Consortium (TCTC) specializes in 13 therapeutic areas
- Central-IRB with 9 authorized medical centers
- IRB Review completes in 20 days
- 6 AAHRPP

Clinical Trial CRO  
BA/BE  
Biologics CMO

**100+ research-focused companies**

Facility	cGMP	PIC/s GMP
Pilot Plant	8	10
API	21	22
Chinese Medicine	97 (GMP)	96 (GMP) (Apr/15/2016)
Finished Product	140	132 (May/2017)

台灣館文宣資料—本屆台灣形象館以「台灣生技創新加值夥伴」及「共創生技醫藥大未來」做為展出主題。

Taiwan Food and Drug Administration  
Ministry of Health and Welfare

Service  
Profession  
Innovation  
Quality

To ensure the  
**QUALITY**  
and  
**SAFETY** of food and medical products.

To safeguard national health and lead the nation into a new era of food and drug management.

Food and Drug Administration, Ministry of Health and Welfare  
TEL: +886-2-2787-8000  
ADD: No. 161-2, Kunyang St, Nangang District, Taipei City 115-61, Taiwan (R.O.C)  
Website: <http://www.fda.gov.tw/EN/index.aspx>

食藥署文宣資料—簡介有關藥品、醫材、食品、化粧品之管理。



## The Ministry of Health and Welfare of the Republic of China

[www.mohw.gov.tw/EN/Ministry/Index.aspx](http://www.mohw.gov.tw/EN/Ministry/Index.aspx)

### Company Description

The Ministry of Health and Welfare of the Republic of China (MOHW) is the ministry of the Republic of China and the highest authority responsible for the administration of the public health system, social welfare, affordable and universal health care, health policy-making, hospitals, pharmaceutical, immunization programs, disease prevention, supervision and coordination of local health agencies in Taiwan.

The Ministry of Health and Welfare's responsibilities include health planning and promotion, prevention and control of disease, food safety, drug management, social insurance, and welfare, relief and protective services. MOHW's mandate also includes biotechnology R&D, international health cooperation, and diverse other areas affecting public health and well-being far beyond Taiwan.

### Contact Information

**Name** Hsien-yang Lee **Position** Post-Doctoral Researcher, Science and Technology Unit  
**Tel** +886-2-8590 7567  
**E-mail** [schylee1460@mohw.gov.tw](mailto:schylee1460@mohw.gov.tw)  
**Address** No. 488, Sec. 6, Zhongxiao E. Rd., Nangang Dist., Taipei City 115, Taiwan (R.O.C.)  
**Sectors** Promoting the Health and Well-Being of All Citizens in Taiwan.

2



## Council of Agriculture Executive Yuan

[www.coa.gov.tw/show\\_index.php](http://www.coa.gov.tw/show_index.php)

### Company Description

Agriculture enhanced and contributed development of Taiwan. The Council of Agriculture (COA), Executive Yuan is the competent authority on the agricultural, forestry, fishery, animal husbandry and food affairs in Taiwan. The Council is committed to promoting the diversified value of agriculture, ensuring food security, preserving agro-ecological environment and cultural landscape, and creating a competitive LOHAS agriculture. The COA is leading the policies toward expediting agricultural structure adjustment, promoting agro-business management, boosting agricultural industry internationalization, activating agricultural resources, in order to ensure the sustainable development of agriculture in Taiwan.

### Contact Information

**Name** Kuo-Chin Huang **Position** Associate technical specialist  
**Tel** +886-2-2381 2991  
**E-mail** [during0604@mail.coa.gov.tw](mailto:during0604@mail.coa.gov.tw)  
**Address** No. 37, Nan Hai Rd., Taipei 10014, Taiwan (R.O.C.)  
**Sectors** Promoting Sustainable Agriculture in Taiwan.

3



## Hsinchu Biomedical Science Park

[www.sipa.gov.tw/english/index.jsp](http://www.sipa.gov.tw/english/index.jsp)

### Company Description

Hsinchu Biomedical Science Park supports the development of new drugs R&D for diseases that are common in Asia, and of high-end medical devices. It integrates the nearby Hsinchu Science Park's ICT value chain with open lab and core facilities served by the National Laboratory to provide services fulfilling all possible demands of innovation entrepreneurs. The hospital under construction is expected to provide over 728 beds for medical treatments and clinical trials when it is completed. In addition, the Park will also develop featured clinics and medical services.

### Contact Information

**Name** May Hsia **Position** Research Associate  
**Tel** +886-3-577 3311  
**E-mail** [may@sipa.gov.tw](mailto:may@sipa.gov.tw)  
**Address** No. 2, Hsin Ann Road, Hsinchu 30016, Taiwan (R.O.C.)  
**Sectors** New Drugs, High-end Medical Devices, Featured Clinics

4



## Southern Taiwan Science Park Bureau, Ministry of Science and Technology

[www.stsp.gov.tw](http://www.stsp.gov.tw)

### Company Description

The biotechnology industry at the Southern Taiwan Science Park (STSP) has been actively developing the visionary biomedical devices, has become one of Taiwan's most important development and manufacturing areas of the medical device industry.

The STSP has taken a proactive role in facilitating the development of medical device industry by integrating medical, industrial, academic, and research resources and providing resident businesses with a holistic service platform.

By demonstrating that high technology industry clusters can also be an environmentally-friendly and high-quality living environment, the STSP has now developed into a bastion of high-tech industry and talented people.

### Contact Information

**Name** Hsiu-Ling Ke **Position** Technical Specialist  
**Tel** +886-6-505 1001 #2119  
**E-mail** [ksl@stsp.gov.tw](mailto:ksl@stsp.gov.tw)  
**Address** No. 22, Nanke 3<sup>rd</sup> Rd., Xinshi District, Tainan City 74147, Taiwan (R.O.C.)  
**Sectors** One-stop Service, Research Ecosystem, Innovative Consultation Platform for Industrial Development, Platform to Boost Clinic Reliability, International Marketing Services Platform

5



## Academia Sinica

www.sinica.edu.tw/en

### Company Description

Since its inception in 1928 in China and then in Taiwan after 1949, Academia Sinica has been at the forefront of advanced research activities and has established outstanding track records in the domains of physical sciences, life sciences, and social sciences and the humanities. In recent decades, the excellence of Academia Sinica has been widely recognized through the success of many international research projects and memberships within the world's most prestigious academic organizations.

### Contact Information

**Name** Hong-Zhang Chen **Position** Licensing Associate

**Tel** +886-2-2787 2556

**E-mail** jameschen@gate.sinica.edu.tw

**Address** No. 128, Section 2, Academia Road, Nankang, Taipei 115, Taiwan (R.O.C.)

**Sectors** Academia/Research Institution, Tech Transfer

6



## Agricultural Technology Research Institute

www.atri.org.tw

### Company Description

Agricultural Technology Research Institute (ATRI) was established on January 1, 2014 supported by Council of Agriculture (COA) with the mission of turning agricultural techno-innovation into techno-entrepreneurship through technology business incubation.

The ATRI possesses diverse agricultural technologies and professional experts, and will combine creative thinking and technical advantages with the R&D energy of the up and middle stream of domestic agricultural research institution(s), to add value to the applications of Taiwan's agricultural technology R&D results, promote industry integration, and with the objectives of enhancing international competitiveness of agricultural products and accelerate Taiwan's agricultural transformation.

### Contact Information

**Name** Liang-Cheng Hung **Position** Chief

**Tel** +886-3-518 5040

**E-mail** eric.hung@mail.atri.org.tw

**Address** No.1, Ln. 51, Dahu Rd., Xiangshan Dist., Hsinchu City 300, Taiwan (R.O.C.)

**Sectors** Agriculture

7



## Development Center for Biotechnology

www.dcb.org.tw

### Company Description

The Development Center for Biotechnology (DCB) of Taiwan is a not-for-profit organization founded in 1984, based on government grants and private donations. DCB's mission is to accelerate the development of Taiwan's biotech industry, by way of building infrastructures, developing key technologies, promoting cooperation and industrialization, and training talented workforces, in coordination with governmental, industrial, and academic institutions.

### Contact Information

**Name** Eric Sun **Position** Public Affairs Senior Specialist

**Tel** +886-2-2695 6933

**E-mail** ericsun@dcb.org.tw

**Address** No. 101, Lane 169, Kang-ning Street, Xizhi Dist., New Taipei City, Taiwan (R.O.C.)

**Sectors** Non-Profit > Research Institution  
Primary Technologies > Drug Development  
Primary Technologies > Plant-made Pharmaceuticals

8



## Industrial Technology Research Institute

www.itri.org.tw

### Company Description

Industrial Technology Research Institute (ITRI) is the leading non-profit R&D organization engaging in applied research and technical services, aiming to innovate a better future. ITRI's Biomedical Technology and Device Research Laboratories (BDL) works to bring about a future of health and happiness. At ITRI BDL, we focus on five core areas of research including **botanical drugs, targeted drug and delivery technology, regeneration medicine, Bio-IT and diagnostics and precision medicine**. We have access to cutting-edge technologies, and provide technology transfer, licensing and other industry services. We would like to extend a hearty welcome to domestic and overseas businesses to file their applications for technology transfer or licensing, prototyping, or other industry services. ISO 13485, GMP, EU/FDA certified.

### Contact Information

**Name** Mary Y. Yeh **Position** Researcher, Planning and Marketing Division

**Tel** +886-3-591 2100

**E-mail** ITRI\_BDL@itri.org.tw

**Address** No. 195, Sec. 4, Chung Hsing Rd., Chutung, Hsinchu 31040, Taiwan (R.O.C.)

**Sectors** Bio-materials and cell therapy; New drugs; Botanical drugs; Drug delivery systems; Cosmetic product R&D; Medical devices for minimally invasive surgery, diagnostics, and imaging; Biomarkers; Services in regulatory, IP, clinical trials

9

**NAR Labs** National Applied Research Laboratories/  
National Nano Device Laboratories

www.narlabs.org.tw

**Company Description**

National Nano Device Laboratories (NDL), founded in 1988, has two branches in Hsinchu Science Park and Southern Taiwan Science Park. NDL has been recognized internationally for the achievement of research and development (R&D) and provided service platforms for the R&D of semiconductor manufacturing and chip-based biomedical technologies. It also supports academia and industries on the R&D of nano-device technologies that involve new materials, structures, and applications, mostly in Taiwan. In addition, NDL has developed a cross-disciplinary research platform for numerous novel research topics of microelectronics, physics, chemistry, optoelectronics, micro-electromechanical systems, mechanical engineering, bio-medical devices and chip-based new drug screening and development.

**Contact Information**

**Name** Hueih-Min Chen **Position** Research Fellow  
**Tel** +886-3-572 6100 #7712 **mobile** +886-921935921  
**E-mail** hmchen@narlabs.org.tw  
**Address** No. 26, Prosperity 1<sup>st</sup> Road, Science Park, Hsinchu 30078, Taiwan (R.O.C.)  
**Sectors** Non-profit Research Institute (Technology Development and Service)

10



National Health Research Institutes (NHRI)

english.nhri.org.tw/NHRI\_WEB/nhriw001Action.do

**Company Description**

The National Health Research Institutes (NHRI) was formally established in 1996 in Taiwan as a government-supported non-profit research organization with the purpose to promote and develop medical and health-related research in order to enhance social welfare for the people. As the only public research institute to focus entirely on human health and a think tank for the Ministry of Health and Welfare in Taiwan, the NHRI's mission is to (a) advance biomedical sciences, (b) promote population and individual health, (c) forge biotechnology and pharmaceutical development, and (d) train and cultivate biomedical researchers. Since December 2004, the NHRI has relocated to its state-of-the-art main campus at Zhunan, which is close to the High-Tech cluster near Hsinchu Area, Taiwan. Currently, the NHRI, as a whole, comprises a community of more than 1,500 employees, including 130+ Principal Investigators, 170+ post-doctoral fellows, 750+ research assistants and 350+ supporting staff.

**Contact Information**

**Name** Richard C. Y. Yeh **Position** Acting Director  
**Tel** +886-3-724 6166 #33200  
**E-mail** richardyyeh@nhri.org.tw  
**Address** No. 35, Keyan Road, Zhunan Township, Miaoli County 35053, Taiwan (R.O.C.)

11



Taiwan Bio Industry Organization  
(BioTaiwan 2017)

www.taiwanbio.org.tw, www.bio-taiwan.com

**Company Description**

Taiwan Bio Industry Organization (TBIO) is the largest and the most influential biotechnology organization in Taiwan. TBIO represents over 300 members ranging from private companies and academic institutes to government bodies involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology. We are a strong arm to foster the development of biotechnology in Taiwan. Our mission is to provide advocacy, business development, international partnership, training and communication service for our members. TBIO organizes the annual BioTaiwan conferences and exhibition, the largest gathering of biotechnology industry in Taiwan.

BioTaiwan 2017, its 15th annual event will be held June 28 - July 2 in Taipei, Taiwan. website: <http://www.bio-taiwan.com>

**Contact Information**

**Name** Bor-Fuei "Apo" Huang **Position** Secretary General  
**Tel** +886-2-2655 8692 #15  
**E-mail** Apohuang2@gmail.com  
**Address** 7F-1, No. 3-2, Yuan-Qu St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.)  
**Sectors** BioTaiwan 2017 (6/28-7/2): opportunities await in Asia's most under-explored biotech location! [www.bio-taiwan.com](http://www.bio-taiwan.com)

12



Taiwan Research-based Biopharmaceutical  
Manufacturers Association (TRPMA)

www.trpma.org.tw

**Company Description**

Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), composed of 30 Taiwanese innovative biopharmaceutical companies, plays a pivotal role in coordinating the resources, strengthening the alliances among the industry, the academic and the government in Taiwan. Our ambition is to create a competitive value chain of biopharmaceutical industry to boost nation's economy and promote the Asian along with global cooperation in biopharmaceutical innovation.

**TRPMA Mission:**

1. Motivate Open Innovation
2. Establish Academia-Industry-Government Platform
3. Promote International Collaboration
4. Build Business Partnership

**Contact Information**

**Name** Tina Chen **Position** Marketing Associate Manager  
**Tel** +886-2-2783 1262  
**E-mail** trpma@trpma.org.tw  
**Address** 1F, No. 465-1, Sec. 6, Zhongxiao E. Rd., Taipei 11557, Taiwan (R.O.C.)  
**Sectors** Biopharma

13



**Company Description**

ACRO Biomedical is in the leading position of the field of collagen derived medical devices that expertizes in tissue engineering and regenerative medicine of human tissues and organs. The high end medical devices were process by using supercritical carbon dioxide extraction technology to remove lipids, cells, and non-collagenous proteins from tissues and organs to create natural collagen scaffolds suitable as xenograft biomaterials for tissue engineering and regenerative medicine applications. The products can be applied to various fields including Wound Care, Dentistry, Orthopedic, Ophthalmology, Aesthetic Microsurgery, Cardiology, and Neurosurgery.

**Contact Information**

**Name** **Patricia Wu** **Position** Secretary to CEO  
**Tel** **+886-7-695 5569** **mobile** **+886-921 935 921**  
**E-mail** **patricia@acrobiomedical.com**  
**Address** 3<sup>rd</sup> Fl., No. 57, Luke 2<sup>nd</sup> Rd., Lujhu Dist., Kaohsiung City 82151, Taiwan (R.O.C.)  
**Sectors** Collagen Matrix, Bone Graft, Collagen Membrane, Collagen Ophthalmic Matrix, Dermal Filler, and Skin Care Products

14

**Company Description**

EirGenix, Inc. is a new Asia Development & Manufacturing Hub for Biologics and offers high quality and cost-effective services to support clients from around the world. The firm owns and operates two cGMP compliant plants, producing microbial and mammalian based biologics all the way from cell line development to final product bulk filling. Additionally it provides assistance in product and process development and analytical testing for all stages starting from pre-clinical stages to commercial manufacturing. EirGenix aims to become the vanguard of Taiwan's antibody drug conjugates (ADC) drug development and hope that not only will it provide quality service and economic solutions to its clients, it will further stimulate the global demand for the drugs.

**Contact Information**

**Name** **Chih-Jung Chang** **Position** Vice President  
**Tel** **+886-2-7708 0123 #6020**  
**E-mail** **cjchang@eirgenix.com**  
**Address** No. 101, Lane 169, Kang Ning Street, Xizhi District, New Taipei City 22180, Taiwan (R.O.C.)  
**Sectors** CDMO, ADC, Biosimilar, Biologics

15

**Company Description**

Foresee is a Taiwan and US-based pharma company listed on the Taipei Exchange. Foresee's R&D efforts are focused on its unique SIF depot delivery platform & derived drug products targeting specialty markets, and its transformative early stage preclinical and clinical NCE programs targeting inflammatory & fibrotic diseases with highly unmet needs. Foresee's product portfolio includes (1) FP-001, a stable, premixed, pre-filled version of leuprolide depot for prostate cancer, whose 97% of phase 3 subjects achieved primary efficacy endpoints; (2) FP-025, a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, which is currently completing a phase 1 study; and (3) FP-045, an oral small molecule ALDH2 agonist, targeting NAFLD/NASH and cardiovascular diseases.

**Contact Information**

**Name** ① **Mathieu Boudreau, Ph.D.** **Position** ① Vice President, Business Development ② **Patricia PEIFEN Chou, M.S.** **CFO**  
**Tel** ① **514-806-9036** ② **+886-2655 2658**  
**E-mail** ① **Mathieu.Boudreau@foreseepharma.com**  
 ② **Patricia.Chou@foreseepharma.com**  
**Address** 3F., No.19-3, Sanchong Rd., Nangang Dist., Taipei City 115, Taiwan (R.O.C.)  
**Sectors** Two core technologies: (1) Drug Delivery Technology: stabilized injectable formulation (SIF); (2) Rational Drug Design: novel new drug (New Chemical Entity, NCE) development

16

**Company Description**

Health Ever Bio-Tech Co., Ltd. (HEB) was established to focus on the research and development of innovative botanical drugs backed with scientific and medical evidences for today's great unmet medical needs. With in-house ISO/IEC 17025 certified laboratory and PIC/S GMP manufacturing facility, HEB has been actively involved in the preclinical and clinical development of botanical new drugs that have been verified effective and safe on animal, cellular and human studies. HEB has built a network of domestic and international scientific advisors and consultants who are top-notch in the industry to maximize the success and quality of our pipeline. HEB endeavors to provide botanical new drugs of the best quality and makes strenuous efforts to improve the health of our compatriots.

**Contact Information**

**Name** **Alex Chen** **Position** Business Development Coordinator  
**Tel** **+886-2-2732 5205**  
**E-mail** **alex.c@hebiotech.com**  
**Address** 5F-6, No. 51, Sec. 2, Keelung Rd., Xinyi Dist., Taipei City 110, Taiwan (R.O.C.)  
**Sectors** Research and Development of Botanical New Drugs

17



## Lumosa Therapeutics Co., Ltd.

www.lumosa.com.tw

### Company Description

Lumosa Therapeutics is dedicated to the development of innovative new drugs for the treatment of neurological and inflammatory diseases with unmet medical needs. The company is actively engaged in scientific licensing and new drug development under the "reSEARCH and DEVELOPMENT" model. We select drug candidates with strong scientific rationale and high feasibility of technical success, and transform them into highly differentiated products. Several novel new drug products with global market potential under development by Lumosa are available for collaborations in clinical trials, product development and for commercialization.

### Contact Information

**Name** Joanne Lo **Position** Manager, Business Development  
**Tel** +886-2-2655 7918 #5731  
**E-mail** Joanne\_lo@lumosa.com.tw  
**Address** 4F, No. 3-2, Park St., Nangang Dist., Taipei City 11503, Taiwan (R.O.C.)  
**Sectors** (1) LT1001 – long-acting analgesic IM injection product  
(2) LT3001 – dual-acting NCE for acute ischemic stroke

18

## Mycenax Biotech Inc. Mycenax Biotech Inc.

www.mycenax.com.tw/en/

### Company Description

Mycenax Biotech Inc.(MBI), the CMC-based biopharmaceutical company, was established in 2001. MBI featured in utilizing the most advanced single-use technology in its USFDA DMF registered and TFDA PIC/S GMP certified biomanufacturing facility, and conducting microbial fermentation in fermenter up to 50 L, and cell culture in bioreactor up to 2,000L. MBI provides high quality, cost-effective, time-efficient and international quality service for developing and manufacturing cGMP drug substance and finished product.

In addition to offering process development and manufacturing services to clients, we focus on biosimilar and bionovel development. MBI is keen to look for strategic partner or co-developer for regional or global development.

### Contact Information

**Name** Jocelyn Lin **Position** Regional BD manager  
**Tel** +886-37-586 988  
**E-mail** Jocelyn.lin@mycenax.com.tw  
**Address** 4F, No. 50-7, Keyan Road, Zhunan Township, Miaoli County 35053, Taiwan (R.O.C.)  
**Sectors** (1) CDMO services  
(2) Biological product development

19



## OBI Pharma, Inc.

www.obipharma.com/en

### Company Description

We are a Biopharma company focusing on developing innovative cancer therapies. Our pipeline focuses on targeting novel therapeutic targets—Globo Series (e.g. Globo H, SSEA 3 & 4). Globo Series are carbohydrate antigens highly expressed in multiple types of cancers. Our novel cancer pipeline focusing on "Globo Series" (Globo H, SSEA 3 & 4) include: (1) OBI-822 Active Immunotherapy in Metastatic Breast Cancer (P2 completed), Ovarian Cancer Trial (P2 ongoing) and other solid tumors (2) OBI-833 active Immunotherapy in solid tumors (P1 ongoing); (3) OBI-888 Globo H mAb in multiple solid tumors (planned); (4) OBI-999 Antibody-Drug Conjugate (ADC) in multiple solid tumors (planned).

### Contact Information

**Name** Kevin Poulos **Position** Chief Commercial Officer  
**Tel** +1 (619) 537-7698 #102  
**E-mail** kpoulos@obipharmausa.com  
**Address** 6020 Cornerstone Court W, Suite 200 San Diego 92121, California  
**Sectors** Biotech, Biopharma, Oncology, Immuno-oncology, Immuno Therapy, Cancer Therapy

20



## PharmaEssentia Corp.

www.pharmaessentia.com

### Company Description

PharmaEssentia Corporation is a global, fully integrated biopharmaceutical company publicly traded and based in Taiwan. The company is headquartered at a state-of-the-art facility in Nankang Science Park in Taipei, and its world-class cGMP manufacturing site is located in Central Science Park in Taichung. PharmaEssentia's mission is to discover, develop, manufacture, and bring to market efficacious, safe, and cost-effective therapies for the treatment of MPN disorders. The company is also undertaking drug research and development initiatives in hematology, infectious diseases, oncology, and dermatology.

### Contact Information

**Name** Shu-Fen Li **Position** Senior Director  
**Tel** +1-857-373 9775  
**E-mail** shufen\_li@pharmaessentia.com  
**Address** 13F, No. 3, Yuan-Qu Street, Nankang District, Taipei 11503, Taiwan (R.O.C.)  
**Sectors** Ropeginterferon alfa-2b (P1101)

21



## Pigmodel Animal Technology Co., Ltd.

www.pigmodel.asia

### Company Description

The mission of Pigmodel is to serve as contract partner of bio-technology industry by using pigs as animal model for pre-clinical trials and bio-medical research. Pigmodel is a complete animal trial facility equipped with professional staff, responsible veterinary care and animal husbandry in accordance with the highest scientific, humane and ethical principles. This is achieved by the development and maintenance of quality animal care program in full compliance with Guide (NRC, 2011) and Taiwan national legislation. Pigmodel provides effective service team for pre-experimental consulting and to accomplish clients' requests and has achieved AAALAC accreditation and National Biotechnology and Medical Care Quality Award in 2016.

### Contact Information

**Name** Dr. Yao-Horng Wang **Position** President  
**Tel** +886-37-433 789  
**E-mail** pigmodel@gmail.com  
**Address** 1F., No. 1021, Gongyi Rd., Zhunan Township, Miaoli County 350, Taiwan (R.O.C.)  
**Sectors** Pharmacokinetics; R&D Services; Regenerative Medicine; Cosmetics; Devices; Customized experimental designs

22



## SLC Savior Lifetec Corporation

www.saviorlifetec.com.tw/en/

### Company Description

Savior Lifetec Corporation (SLC) is a specialty injectable company based in Chunan, Taiwan. Our state of the art facilities are vertically integrated, capable of producing sterile API and finished dosage formulations. Our facilities comply with the highest quality standards, having passed inspections by authorities from the US, EU, and Japan. SLC also has dedicated state-of-the-art GLP compliant R&D centers for API research and pharmaceutical research. SLC's expertise in sterile crystallization and the aseptic processing of sterile powder serves as the foundation for product innovation.

SLC is targeting high barrier non-penem drug candidates. These non-penem products will leverage SLC's expertise in sterile crystallization and the aseptic processing of sterile powder. Eventual manufacturing will occur in Zhunan, Taiwan.

### Contact Information

**Name** Amy Liu **Position** Manager  
**Tel** +886-37-580 100 #1040/2600  
**E-mail** amy.liu@saviorlifetec.com.tw  
**Address** No. 29, Ke-Jhong Rd., Zhunan Township, Miaoli County 35053, Taiwan (R.O.C.)  
**Sectors** Pharma: API  
Pharma: Small Molecular Drug  
Pharma: Biologics

23



## Simpson Biotech Co., Ltd.

www.simpsonbiotech.com

### Company Description

Simpson Biotech Co., Ltd.(SBC), established in 1998, is a privately held company located in Taipei, Taiwan focusing on 1> **Bacteria Rapid Detection System** based on magnetic beads coated with its patent pending "SimpTrap™" molecule that can bind almost all bacteria for foodborne pathogen or gut microbiome detection. 2> Fermentation of medicinal fungus and the enzymatic hydrolysis of natural ingredients for dietary supplements and early stage drug discovery. 3> The development and the fermentation of recombinant proteins and industrial enzymes using patented proteins purification platform. Simpson Biotech has won numerous awards and holds more than 39 issued patents with another 21 pending.

### Contact Information

**Name** Evelyn Wang **Position** Secretary  
**Tel** +886-3-396 3466  
**E-mail** service@simpsonbiotech.com  
**Address** No. 1-1, Wen Min 2<sup>nd</sup> St., Kuei Shan, Taoyuan 333, Taiwan (R.O.C.)  
**Sectors** (1) Bacteria Rapid Detection  
(2) Anti-inflammation drug  
(3) Natural dietary supplement  
(4) Recombinant protein

24



## SynCore Bio Syncore Biotechnology Co., Ltd.

www.syncorebio.com

### Company Description

#### About SynCore

SynCore Biotechnology Co., Ltd (SynCore) (4192:TT) is a biopharmaceutical company with a comprehensive pipeline portfolio of new drugs in the areas of oncology, ophthalmology, dermatology and infectious diseases. Please visit the Company's website at <http://www.syncorebio.com/>

For further information please contact:

Media: Charles Liang, CFO [finance@syncorebio.com](mailto:finance@syncorebio.com)  
Business Development: [BD@syncorebio.com](mailto:BD@syncorebio.com)

### Contact Information

**Name** **Position**  
**Tel**  
**E-mail**  
**Address** 4F, No. 69, DongXing Rd., XinYi Dist., Taipei City 110, Taiwan (R.O.C.)  
**Sectors** SynCoreBio is a public listed company established in 2008, focusing on new drugs R&D. SynCoreBio owns a comprehensive pipeline with 5 new drugs: SB01 (Phase2, Head and Neck Cancer); SB02 (Pre-IND, Solid Tumors); SB03 (FDA approval, External Genital Warts); SB04 (Phase2, dry AMD); SB05(Phase3, Pancreatic Cancer/Triple-Negative Breast Cancer).

25



## TaiGen Biotechnology

www.taigenbiotech.com.tw

### Company Description

TaiGen Biotechnology, a public listed company in Taipei Exchange (4157.TWO), is a leading research-based biotechnology company in Taiwan. TaiGen's pipeline includes in-house discovered and developed new chemical entities: Taigexyn®, a novel antibiotic, is one of the first NCEs developed by a Taiwanese company that received market approval and launched in Taiwan and mainland China. Burixafor, a chemokine receptor antagonist, completed Phase 2 clinical trial for stem cell transplantation in the U.S. Fupaprevir, a HCV NS3/4A protease inhibitor, completed Phase 2 clinical trial in HCV genotype 1b patients in Taiwan. In 2016, TaiGen Biotechnology signed an agreement to form a new company with YiChang HEC ChangJiang Pharmaceutical Co., Ltd. in mainland China for the joint development and commercialization of direct-acting antiviral agents (DAAs) for HCV treatment in the Greater China region.

### Contact Information

**Name** Peter W. Tsao **Position** Senior Vice President of Business Development  
**Tel** +886-2-8177 7072  
**E-mail** ptsao@taigenbiotech.com  
**Address** 7F, No. 138, Shin Ming Rd., Neihu Dist., Taipei 11470, Taiwan (R.O.C.)  
**Sectors** TaiGen Biotechnology focuses in the research and development of New Chemical Entities (NCEs). TaiGen's pipeline includes first-in-class and best-in-class treatment for infectious diseases, oncology and diabetes-related complications.

26



## Taiwan Leader Biotech Corp.

www.twleaderlife.com/en/

### Company Description

Taiwan Leader Biotech Corp. is the leader brand of Taiwan unique medicinal fungus- Taiwanofugus camphoratus (Antrodia cinnamomea) industry.

We are devoted to Cinnamomum kanehirae Hayata reforestation and has obtained international Forest Stewardship Council (FSC) certification (FSC-FM/COC) verify by NGO organization - Rainforest Alliance (RA).

We obtained the approval from US FDA to conduct Phase I/IIa clinical trials, for botanical drug, LEAC-102

The leading company obtained the largest number of T. camphoratus raw materials legal permits approved by TFDA.

Taiwan Leader Biotech Corp provides "Safety, quality and expertise" products and services with a variety of ways of cooperation!

### Contact Information

**Name** Darren Lin **Position** Business Development Specialist  
**Tel** +886-2-2559 2777 #622  
**E-mail** LESD@twleaderlife.com  
**Address** 13F-1, No. 81, Sec. 2, Chengde Rd., Taipei City 10353, Taiwan (R.O.C.)  
**Sectors** Specialized on T. camphoratus materials/ health supplements/ cosmetics/ general food and beverage, OEM and ODM

27



## TLC (Taiwan Liposome Company, Ltd.)

Estimating hope for life

www.tlcbio.com

### Company Description

Based in Taipei, TLC is a commercial stage biopharmaceutical company developing novel nanomedicines for cancer, ophthalmic conditions and pain management that maximize the potential of its proprietary lipid-based drug delivery technology. TLC's highly scalable and versatile technology enables the development of sustained release and targeted therapies capable of reducing toxicities and improving effectiveness. Advanced programs include TLC388 in liver cancer, TLC399 for diseases of the eye and TLC599 for osteoarthritis pain. TLC has global commercial partnerships, an experienced drug development and commercialization team and subsidiary offices in the US, the Netherlands, China, Hong Kong, Australia and Japan.

### Contact Information

**Name** Wenji Chen, Ph.D. **Position** Vice President, Corporate Development Division  
**Tel** +886-2-2655 7377  
**E-mail** wenji@tlcbio.com  
**Address** 2F, No. 3, Yuanqu St., Nangang Dist., Taipei 115, Taiwan (R.O.C.)  
**Sectors** Drug Delivery System, Targeted Delivery, Sustained Release, Oncology, Ophthalmology, Pain Management

28



## TPG Biologics, Inc.

www.tpgbiologics.com


### Company Description

TPG Biologics is a biotechnology company that specializes in the early stage research and development of biologics. We are a multifaceted biotech company that provides CRO services and monoclonal and protein biosimilar cell lines. This diversity is made possible by our well-established and state-of-the-art technology platforms, as well as our highly-skilled and dedicated scientists. Our mission is to be the best partner for worldwide pharmaceutical and biotech companies. At TPG, we work to tailor each project to our clients' wishes, communicating individually with them to ensure outstanding results.

### Contact Information

**Name** Pei-Jiun Chen **Position** President  
**Tel** +886-2-2655 8951  
**E-mail** Peijiun.chen@tpgbiologics.com  
**Address** 17F, Building F, No. 3, Yuan Qu Street, NanKang District, Taipei 115, Taiwan (R.O.C.)  
**Sectors** (1) CRO services for cell line and process development  
(2) mAb and protein biosimilar production clones

29

 **United BioPharma, Inc.**  
www.unitedbiopharma.com/eng/index.html

**Company Description**

**United Biomedical, Inc. Group of Companies**

- UBI was established in 1985 with HQ in Long Island, New York, USA
- United BioPharma specializes in biologics development and manufacturing
- UBI Pharma offers both biologics products and small molecule products

**CMO/CDMO: Integrated Solution Provider**

**Biologics Solutions:**

- Process Development for Biopharmaceuticals

**Small Molecules Solutions:**

- Formulation Development
- GMP Contract Manufacturing

**Track records:**

- Global Partners: Pfizer, MSD, GSK, Aspen, Astellas
- USA (FDA): approved sterile injectable line
- Japan (PMDA): approved sterile injectable line
- Australia (TGA): approved ointment line
- Colombian BoH (INVIMA): approved ointment line

**Contact Information**

**Name** Peter Tang **Position** BD Manager

**Tel** +886-3-597-9288 #6310


**E-mail** peter.tang@unitedbiopharma.com

**Address** No. 45-1, Guangfu N Rd., Hukou Township, Hsinchu County 30351, Taiwan (R.O.C.)

**Sectors**

- Cell line development
- cGMP cell bank
- Process development
- cGMP contract manufacturing
- Analytical solutions

30

 **VETCO Vetco Pharmaceuticals Inc.**  
www.vetcogroup.com

**Company Description**

Vetco is a Taiwanese veterinary pharmaceutical company, focused on developing novel products to supply the needs of untapped market in the veterinary industry. We are devoted to providing veterinary professionals with innovative therapeutic solutions to improve the well-being of animals and owners.

Vetco has successfully developed the first pet anticancer drug in Asia, Antican®, which will be launched in Taiwan in 2017. Besides Taiwan, Vetco would also work to bring this product to its full potential onto the global stage through the collaboration with international pharmaceutical companies who share the same view with us.

**Contact Information**

**Name** Wun-Yan Huang **Position** Public relation

**Tel** +886-2-2977 5757 #29

**E-mail** khuang@vetcogroup.com

**Address** 20F, No. 97, Sec. 4, Chongxin Rd., Sanchong Dist., New Taipei City 241, Taiwan (R.O.C.)

**Sectors** Antican® is a safe, effective, and broad-spectrum drug and can mitigate the issue of undeveloped pet oncology market.

31

台灣館參展單位列表—以講求簡單明瞭的方式條列國內各家優秀廠商及研究單位，內容言簡意賅，可提高媒合研究員與其他單位的合作機會，藉以有效的成功拓展國際合作夥伴關係。



2018 北美生技展(2018 Bio International Convention)宣傳資訊，將於麻薩諸塞州波士頓舉辦。